Total amount: € 0,00
Indexed/Abstracted in: BIOSIS Previews, EMBASE, Scopus, Emerging Sources Citation Index
Online ISSN 1827-1812
Mattioli P. L. 1, Palazzini E. 2
1 University of Reggio Calabria, School of Medicine, Chair of Internal Medicine, Policlinico Mater Domini - Catanzaro;
2 Medical Department - Alfa Wassermann SpA, Bologna
Methods. Forty patients suffering from radiculitis (30 cases) and fibromyositis (10 cases) were treated with 150 mg of oral diclofenac sodium/day for 30 days. Two differing posology schemes were applied to patients: one group (15 cases with radiculitis and 5 with fibromyositis) was administered daily one controlled-release capsule containing 150 mg of the NSAID under study; the other group (15 with radiculitis and 5 with fibromyositis) was administered one enteric-coated tablet containing 50 mg of diclofenac sodium every 8 hours. Drug effectiveness was monitored during treatment registering the changes in VAS values and symptom scores, as well as in some laboratory tests (ESR, C-reactive protein, Rheuma test); drug safety was controlled through the routine laboratory tests of systemic tolerability and by checking local tolerance at the gastrointestinal level.
Results. The same dosage regimen produced, in the two groups, very similar efficacy results: intensity of pain and severity of the other symptoms and signs were clearly and progressively reduced without statistically significant differences. Systemic tolerability was also similarly good in the two groups; from the gastric tolerability point of view, on the contrary, the once-a-day administration scheme was decidedly better tolerated, since no patient complained of local adverse manifestations, against slight and transient episodes (epigastralgia: 3 cases, epigastralgia and nausea: 1 case) detected in the comparison group.